{"address1": "301 Binney Street", "address2": "Suite 402", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "617 401 9975", "website": "https://www.synlogictx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.", "fullTimeEmployees": 72, "companyOfficers": [{"maxAge": 1, "name": "Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc", "age": 46, "title": "President, CEO & Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": 872086, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Antoine  Awad", "age": 42, "title": "Chief Operating Officer", "yearBorn": 1980, "fiscalYear": 2022, "totalPay": 566555, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Timothy K. Lu M.D., Ph.D.", "age": 41, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James J. Collins Ph.D.", "age": 56, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1966, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary Beth Dooley", "title": "VP & Head of Finance", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brendan St. Amant", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ajay  Munshi", "title": "Vice President of Corporate Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Thomas", "title": "Chief People Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Caroline B. Kurtz Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Molly  Harper", "age": 45, "title": "Chief Business Officer", "yearBorn": 1977, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.87, "open": 2.84, "dayLow": 2.78, "dayHigh": 3.06, "regularMarketPreviousClose": 2.87, "regularMarketOpen": 2.84, "regularMarketDayLow": 2.78, "regularMarketDayHigh": 3.06, "payoutRatio": 0.0, "beta": 1.164, "forwardPE": -0.9379085, "volume": 33245, "regularMarketVolume": 33245, "averageVolume": 123553, "averageVolume10days": 35660, "averageDailyVolume10Day": 35660, "bid": 2.86, "ask": 2.89, "bidSize": 1400, "askSize": 1200, "marketCap": 26373434, "fiftyTwoWeekLow": 0.234, "fiftyTwoWeekHigh": 5.708, "priceToSalesTrailing12Months": 37.250614, "fiftyDayAverage": 2.26002, "twoHundredDayAverage": 0.96642, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 10935061, "profitMargins": 0.0, "floatShares": 4920071, "sharesOutstanding": 9189350, "sharesShort": 90782, "sharesShortPriorMonth": 102078, "sharesShortPreviousMonthDate": 1697155200, "dateShortInterest": 1700006400, "sharesPercentSharesOut": 0.0099, "shortRatio": 1.99, "shortPercentOfFloat": 0.0115, "impliedSharesOutstanding": 9189350, "bookValue": 9.439, "priceToBook": 0.30405763, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -59444000, "trailingEps": -12.68, "forwardEps": -3.06, "lastSplitFactor": "1:7", "lastSplitDate": 1503878400, "enterpriseToRevenue": 15.445, "enterpriseToEbitda": -0.183, "52WeekChange": 3.0715308, "SandP52WeekChange": 0.1655178, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SYBX", "underlyingSymbol": "SYBX", "shortName": "Synlogic, Inc.", "longName": "Synlogic, Inc.", "firstTradeDateEpochUtc": 1443619800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "30bbb3c7-ab0a-33b2-91a8-e57d2c890111", "messageBoardId": "finmb_268899196", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.87, "targetHighPrice": 75.0, "targetLowPrice": 35.0, "targetMeanPrice": 56.67, "targetMedianPrice": 60.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 33415000, "totalCashPerShare": 3.636, "ebitda": -59655000, "totalDebt": 18199000, "quickRatio": 3.654, "currentRatio": 4.132, "totalRevenue": 708000, "debtToEquity": 41.929, "revenuePerShare": 0.151, "returnOnAssets": -0.39734, "returnOnEquity": -0.82658, "grossProfits": 1180000, "freeCashflow": -35190376, "operatingCashflow": -58479000, "revenueGrowth": -0.42, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -32.11959, "financialCurrency": "USD", "trailingPegRatio": null}